Resilience Inks Collaboration Deal With Mayo Clinic Over Biotherapeutics

Resilience has inked a collaboration deal with the Mayo Clinic in biomanufacturing to deliver biotherapeutics for rare and complex conditions.

The focus of the deal will be on therapies derived from biologics such as cells, blood, enzymes, tissues, genes or genetically engineered cells. The partners plan on advancing biologic discoveries toward early-stage clinical trials.

“By combining our organizations’ capabilities in biomanufacturing and medical innovation, we have an opportunity to deliver complex and innovative therapeutics to patients in need,” said Resilience CEO Rahul Singhvi.

The financial terms of the deal were not disclosed.